Development of New Molecular Targets and Therapeutic Approaches against Multidrug-Resistant Cancers
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: closed (15 August 2023) | Viewed by 9699
Special Issue Editor
Special Issue Information
Dear Colleagues,
Multidrug resistance (MDR) is a major clinical obstacle in cancer therapy, and many researchers have focused on the molecular pathway of MDR cancer cells as a strategy for the development of new molecular targets. It has been shown that the constitutive expression of ABCB1 is involved in the HGF/Met-related pathway of ABCB1-positive human hepatocellular carcinoma cell lines. Furthermore, leukemia cell lines overexpressing the ABCB1 gene are also shown to be more resistant to the tyrosine kinase inhibitor imatinib mesylate. These findings suggest that chemoresistant cancer cells may also develop a similar mechanism against c-MET inhibitors and that these cells should be added to the extensive list of drugs used in treatment of cancers that are affected by MDR.
This Special Issue, entitled “Development of new molecular targets and therapeutic approaches against multidrug-resistant cancers”, invites researchers to contribute original research articles, review articles, and short communications related to all aspects of developing new molecular targets and therapeutic approaches against multidrug-resistant cancers, as well as molecular mechanisms of multidrug resistance in cancer.
Prof. Dr. Kowit-Yu Chong
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- multidrug resistance
- anticancer drugs
- therapeutic targets
- inhibitor
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
